// App-Quantinova.ai

SO-9 : Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo

Researchers

Presenter

  • A. El-Khoueiry

Principal Investigators

  • T. Meyer

  • A. Cheng

  • L. Rimassa

  • S. Sen

  • S. Milwee

  • R. Kelley

  • G. Abou-Alfa

Medical Centers

  • Norris Comprehensive Cancer Center,Los Angeles,United States

  • The Royal Marsden Hospital, London, United Kingdom

  • National Taiwan University College of Medicine, Taipei, Taiwan

  • Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy, Humanitas University, Rozzano, Pieve Emanuele, Italy

  • Exelixis Inc, Alameda, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY

Locations

  • United States

  • United Kingdom

  • Taiwan

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Sorafenib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved